Avery Lachance is a Dermatology physician affiliated with Brigham and Women's Hospital. OpenAlex indexes 139 publications with 986 citations (h-index 15).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
221 Longwood Ave
Boston, MA 02115
Telephone
617-582-4918Registry record last updated 30 Jan 2019.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20257 payments
- PFIZER INC.Program year20252 payments
- UCB, Inc.Program year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
42%Interleukin-17A Antagonist8.6%Taltz Autoinjector51%Taltz Autoinjector (2 Pack)20%Cosentyx Sensoready (2 Pens)17%Taltz Syringe13%Part D<11 patientsFolate Analog Metabolic Inhibitor7.9%Methotrexate75%Methotrexate Sodium25%Part D<11 patients+ 7 more classes in this area
Dermatology
15.6%Interleukin-4 Receptor alpha Antagonist10.3%Dupixent Pen50%Dupixent Syringe50%Part D<11 patientsCorticosteroid4.3%Triamcinolone Acetonide100%Part D≥32 patients+ 1 more class in this area
Sensory organs
14.6%Corticosteroid14.6%Clobetasol Propionate40%Betamethasone Diprop Augmented25%Betamethasone Dipropionate22%Betamethasone Valerate7%Hydrocortisone7%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Improvement in dermatomyositis-associated muscle disease with anifrolumab
British Journal of Dermatology
2025 - A Case Series of TNF Inhibitor-Induced Psoriasis Successfully Treated With Upadacitinib
Journal of Drugs in Dermatology
2024 - Distinctive cutaneous features of dermatomyositis in Black adults: A case series
JAAD Case Reports
2023 - Successful Treatment of Keloids and Hypertrophic Scars With Systemic and Intralesional Dupilumab
Journal of Drugs in Dermatology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Paul Ridker, MD
Brigham and Women's Hospital
Scott Solomon, MD
Brigham and Women's Hospital
Dennis Selkoe, MD
Brigham and Women's Hospital
Marc Pfeffer, MD
Brigham and Women's Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”